BR112013031685B1 - Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas - Google Patents

Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas Download PDF

Info

Publication number
BR112013031685B1
BR112013031685B1 BR112013031685-3A BR112013031685A BR112013031685B1 BR 112013031685 B1 BR112013031685 B1 BR 112013031685B1 BR 112013031685 A BR112013031685 A BR 112013031685A BR 112013031685 B1 BR112013031685 B1 BR 112013031685B1
Authority
BR
Brazil
Prior art keywords
atec
formulation
plga
eye
release
Prior art date
Application number
BR112013031685-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013031685A2 (pt
Inventor
Vernon G. Wong
Louis L. Wood
Glenn T. Huang
Original Assignee
Icon Bioscience, Inc.
Ramscor, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icon Bioscience, Inc., Ramscor, Inc filed Critical Icon Bioscience, Inc.
Publication of BR112013031685A2 publication Critical patent/BR112013031685A2/pt
Publication of BR112013031685B1 publication Critical patent/BR112013031685B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013031685-3A 2011-06-10 2012-06-11 Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas BR112013031685B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (2)

Publication Number Publication Date
BR112013031685A2 BR112013031685A2 (pt) 2017-02-07
BR112013031685B1 true BR112013031685B1 (pt) 2021-04-06

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031685-3A BR112013031685B1 (pt) 2011-06-10 2012-06-11 Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas

Country Status (22)

Country Link
US (1) US9814773B2 (https=)
EP (1) EP2717914B1 (https=)
JP (1) JP6339011B2 (https=)
KR (1) KR20140060274A (https=)
CN (1) CN103945865B (https=)
AU (1) AU2012304909B2 (https=)
BR (1) BR112013031685B1 (https=)
CA (1) CA2838289C (https=)
CY (1) CY1122771T1 (https=)
DK (1) DK2717914T3 (https=)
ES (1) ES2761340T3 (https=)
HR (1) HRP20192276T1 (https=)
HU (1) HUE047737T2 (https=)
IN (1) IN2013MN02384A (https=)
LT (1) LT2717914T (https=)
MX (1) MX359119B (https=)
PL (1) PL2717914T3 (https=)
PT (1) PT2717914T (https=)
RS (1) RS60051B1 (https=)
SI (1) SI2717914T1 (https=)
SM (1) SMT202000021T1 (https=)
WO (1) WO2013036309A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102245354B1 (ko) * 2013-05-24 2021-04-30 아이콘 바이오사이언스, 인크. 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도
US11730716B2 (en) * 2014-05-08 2023-08-22 Kiora Pharmaceuticals Gmbh Compounds for treating ophthalmic diseases and disorders
US11090296B2 (en) * 2015-03-18 2021-08-17 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
CN107708738B (zh) * 2015-07-01 2022-03-25 参天制药株式会社 含有柠檬酸酯的贮库制剂
JP6949820B2 (ja) 2015-08-03 2021-10-13 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
US11097061B2 (en) 2018-02-09 2021-08-24 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
CA3097926A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4670713A1 (en) 2018-05-01 2025-12-31 Chibi, Inc. LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL
JP2023526512A (ja) 2020-05-22 2023-06-21 トラスティーズ オブ ボストン ユニバーシティ 線維化疾患を処置するための方法および組成物
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
NZ523385A (en) * 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
CA2527664A1 (en) * 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2269663B1 (en) * 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite

Also Published As

Publication number Publication date
JP6339011B2 (ja) 2018-06-06
US20140140992A1 (en) 2014-05-22
PT2717914T (pt) 2019-12-18
AU2012304909B2 (en) 2017-06-08
EP2717914A2 (en) 2014-04-16
NZ619707A (en) 2015-01-30
KR20140060274A (ko) 2014-05-19
SMT202000021T1 (it) 2020-03-13
WO2013036309A2 (en) 2013-03-14
HUE047737T2 (hu) 2020-05-28
ES2761340T3 (es) 2020-05-19
WO2013036309A3 (en) 2013-05-10
BR112013031685A2 (pt) 2017-02-07
IN2013MN02384A (https=) 2015-06-12
US9814773B2 (en) 2017-11-14
AU2012304909A1 (en) 2013-12-19
EP2717914A4 (en) 2015-05-13
CN103945865A (zh) 2014-07-23
MX2013014461A (es) 2014-05-14
MX359119B (es) 2018-09-14
HRP20192276T1 (hr) 2020-05-15
SI2717914T1 (sl) 2020-07-31
CA2838289C (en) 2019-09-10
LT2717914T (lt) 2020-03-25
JP2014516087A (ja) 2014-07-07
CY1122771T1 (el) 2021-05-05
CN103945865B (zh) 2016-10-26
DK2717914T3 (da) 2020-01-20
RS60051B1 (sr) 2020-04-30
CA2838289A1 (en) 2013-03-14
EP2717914B1 (en) 2019-10-30
PL2717914T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
BR112013031685B1 (pt) Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas
Kang-Mieler et al. Advances in ocular drug delivery systems
Liu et al. Characterization of biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of ranibizumab
Herrero-Vanrell et al. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies
CN101060831B (zh) 可方便植入的缓释药物组合物
EP3233056B1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
Iyer et al. Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
KR20170101925A (ko) 병용 요법
CA2957548A1 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP2021521173A (ja) 眼内薬物送達用の持続放出微粒子のための方法及び組成物
Ham et al. Novel drug delivery methods and approaches for the treatment of retinal diseases
Boddu et al. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema
ES2616296T3 (es) Micropartículas de liberación controlada
Pandya et al. Design and Evaluation of Long Acting Biodegradable PLGA Microspheres for Ocular Drug Delivery
HK1196081A (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
HK1196081B (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
NZ619707B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
Marques et al. PKPD of PLGA-PEG-PLGA Copolymeric Micelles
Karagoz et al. Producing Aflibercept Loaded Poly (Lactic Co Glycolic Acid)[Plga] Nanoparticles As A New Ocular Drug Delivery System and Its Challenges
Trinh et al. Novel strategies for the treatment of diabetic macular edema
Rodriguez et al. Monolithic Devices for Sustained Delivery of Protein Therapeutics for Ocular Disease
Fan et al. Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits
WO2024206077A2 (en) Dosing regimes and combination therapies using archexin for the treatment of cancer
Stewart Investigational Medications

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/06/2012, OBSERVADAS AS CONDICOES LEGAIS.